Patents by Inventor Armanda Casrouge

Armanda Casrouge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS
    Publication number: 20120171158
    Abstract: The present invention relates to methods for the treatment of infection, a disease, or a condition using CD26 (DPIV) inhibitors. The present invention also relates to an antibody that binds to the IP-10 protein and a method of monitoring the necessity for administering a CD26 inhibitor to a patient, comprising evaluating a level of sIP-10, a activity of CD26, and/or a level of CXCR3 cells in a sample.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 5, 2012
    Applicant: INSTITUT PASTEUR
    Inventors: Matthew Albert, Armanda Casrouge, Jeremie Decalf, Stanislas Pol, Arnaud Fontanet, Mostafa Mohamed
  • Methods of using sIP-10, CD26 inhibitors and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections
    Patent number: 8124332
    Abstract: The present invention relates to methods for the treatment of infection, a disease, or a condition using CD26 (DPIV) inhibitors. The present invention also relates to an antibody that binds to the IP-10 protein and a method of monitoring the necessity for administering a CD26 inhibitor to a patient, comprising evaluating a level of sIP-10, a activity of CD26, and/or a level of CXCR3 cells in a sample.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: February 28, 2012
    Assignee: Institut Pasteur
    Inventors: Matthew Albert, Armanda Casrouge, Jeremie Decalf, Stanislas Pol, Arnaud Fontanet, Mostafa Mohamed
  • METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS
    Publication number: 20100040577
    Abstract: The present invention relates to methods for the treatment of infection, a disease, or a condition using CD26 (DPIV) inhibitors. The present invention also relates to an antibody that binds to the IP-10 protein and a method of monitoring the necessity for administering a CD26 inhibitor to a patient, comprising evaluating a level of sIP-10, a activity of CD26, and/or a level of CXCR3 cells in a sample.
    Type: Application
    Filed: July 31, 2009
    Publication date: February 18, 2010
    Applicant: INSTITUT PASTEUR
    Inventors: Matthew Albert, Armanda Casrouge
  • Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
    Patent number: 6153408
    Abstract: An altered MHC class I determinant comprises .alpha..sub.1, .alpha..sub.2, .alpha..sub.3, .beta..sub.2 -microglobulin (.beta..sub.2 m) polypeptide domains encoded by a mammalian MHC class I locus in which the .alpha..sub.3 domain is covalently linked to the .beta..sub.2 M domain. An altered MHC class II determinant comprises .alpha..sub.1, .alpha..sub.2, .beta..sub.1, and .beta..sub.2 polypeptide domains encoded by a mammalian MHC class II locus, in which the domains are covalently linked to form a polypeptide comprising the .beta..sub.2 -.alpha..sub.2 -.alpha..sub.1 -.beta..sub.1 domains in sequence. The altered MHC class I and class II determinants can be associated with an antigen to elicit an immune response. The invention can be used in the immunization or treatment of diseases such as AIDS, multiple sclerosis, lupus erythematosus, toxic shock or snake bite.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: November 28, 2000
    Assignee: Institut Pasteur and Institut National de la Sante et de la Recherche Medicale
    Inventors: Jean-Pierre Abastado, Estelle Mottez, Philippe Kourilsky, Armanda Casrouge, David Ojcius, Yu-Chun Lone